Megan Foley

This inventor holds 8 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignees: Proteostasis Therapeutics, Inc., Kineta, Inc.. Active years: 2016-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Megan Foley. Retrieved from https://idiyas.com/inventor/megan-foley

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 8 (Patent Applications = 3)

% Patents Active = 87.5

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 4.2

ph-index = 2

Forward Citations = 15(Granted Patents)

Location History:

Somerville, MA (US) (2023)
Cambridge, MA (US) (2016 - 2024)

Company Filing History:

6 out of 24

Proteostasis Therapeutics, Inc.

Years Active: 2016-2024

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12180189 - Proteostasis regulators (2024-12-31),

2. 11958873 - Proteasome activity enhancing compounds (2024-04-16),

3. 11746098 - Proteasome activity enhancing compounds (2023-09-05),

4. 11242361 - Proteasome activity enhancing compounds (2022-02-08),

5. 10532996 - Proteostasis regulators (2020-01-14),

6. 9850262 - Proteasome activity enhancing compounds (2017-12-26),

7. 9556166 - Proteostasis regulators (2017-01-31),

8. 9399647 - Proteasome activity modulating compounds (2016-07-26),

Title: The Innovative Contributions of Megan Foley

Introduction

Megan Foley is a prominent inventor based in Cambridge, MA, known for her significant contributions to the field of proteostasis. With a total of eight patents to her name, she has made remarkable strides in developing compounds that address various conditions associated with proteostasis dysfunction.

Latest Patents

Megan Foley's latest patents include innovative compounds designed to regulate proteostasis. One of her notable inventions is directed to compounds having specific formulae, including (Ia-Ie), (II), (IIIa-IIId), (IVa-IVc), (Va-Vb), (VIa-VIe), (VII), (VIIIa-VIIIc), and (IX). These compounds, along with their pharmaceutically acceptable salts, prodrugs, and solvates, are aimed at treating conditions linked to proteostasis dysfunction. Another significant patent focuses on proteasome activity enhancing compounds, which also includes various compositions and methods for treatment.

Career Highlights

Throughout her career, Megan has worked with leading companies in the biotechnology sector, including Proteostasis Therapeutics, Inc. and Kineta, Inc. Her work has been instrumental in advancing therapeutic options for patients suffering from proteostasis-related conditions.

Collaborations

Megan Foley has collaborated with notable professionals in her field, including Matthew Cullen and Bradley Tait. These partnerships have contributed to her innovative research and development efforts.

Conclusion

Megan Foley's contributions to the field of proteostasis through her patents and collaborations highlight her role as a leading inventor. Her work continues to pave the way for advancements in medical treatments related to proteostasis dysfunction.

Profile summary based on public USPTO records.